Literature DB >> 11096473

Sudden Electrical Death.

.   

Abstract

Survivors of an episode of out-of-hospital ventricular fibrillation (not due to a reversible cause) or hemodynamically significant sustained ventricular tachycardia should in most cases receive an implantable cardioverter defibrillator (ICD) rather than antiarrhythmic drug therapy. A number of recently published clinical trials (summarized later) point to improved survival with ICD implantation. It is also important to identify the cause of the ventricular rhythm and to treat adequately the underlying cardiomyopathy with the appropriate angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, and aspirin. The role of electrophysiologic study is a matter of debate, and it is used less commonly than it was a decade ago.

Entities:  

Year:  1999        PMID: 11096473     DOI: 10.1007/s11936-999-0011-y

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  16 in total

1.  ICD versus drugs in cardiac arrest survivors: preliminary results of the Cardiac Arrest Study Hamburg.

Authors:  J Siebels; R Cappato; R Rüppel; M A Schneider; K H Kuck
Journal:  Pacing Clin Electrophysiol       Date:  1993-03       Impact factor: 1.976

2.  Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators.

Authors:  A J Moss; W J Hall; D S Cannom; J P Daubert; S L Higgins; H Klein; J H Levine; S Saksena; A L Waldo; D Wilber; M W Brown; M Heo
Journal:  N Engl J Med       Date:  1996-12-26       Impact factor: 91.245

3.  Implantable cardioverter-defibrillators: not the ultimate gold standard for gauging therapy of VT/fibrillation.

Authors:  B N Singh
Journal:  Am J Cardiol       Date:  1994-06-15       Impact factor: 2.778

4.  Implantable cardioverter-defibrillator. Lifesaver or a device looking for a disease?

Authors:  D P Zipes
Journal:  Circulation       Date:  1994-06       Impact factor: 29.690

5.  Canadian Implantable Defibrillator Study (CIDS): study design and organization. CIDS Co-Investigators.

Authors:  S J Connolly; M Gent; R S Roberts; P Dorian; M S Green; G J Klein; L B Mitchell; R S Sheldon; D Roy
Journal:  Am J Cardiol       Date:  1993-11-26       Impact factor: 2.778

6.  Survival after implantation of the cardioverter defibrillator.

Authors:  D Newman; M J Sauve; J Herre; J J Langberg; M A Lee; C Titus; J Franklin; M M Scheinman; J C Griffin
Journal:  Am J Cardiol       Date:  1992-04-01       Impact factor: 2.778

7.  A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias.

Authors: 
Journal:  N Engl J Med       Date:  1997-11-27       Impact factor: 91.245

8.  Long-term outcome with the automatic implantable cardioverter-defibrillator.

Authors:  R A Winkle; R H Mead; M A Ruder; V A Gaudiani; N A Smith; W S Buch; P Schmidt; T Shipman
Journal:  J Am Coll Cardiol       Date:  1989-05       Impact factor: 24.094

9.  Use of implantable cardioverter-defibrillators in the congenital long QT syndrome.

Authors:  W J Groh; M J Silka; R P Oliver; B D Halperin; J H McAnulty; J Kron
Journal:  Am J Cardiol       Date:  1996-09-15       Impact factor: 2.778

10.  Management of ventricular arrhythmias: detection, drugs, and devices.

Authors:  D S Cannom; E N Prystowsky
Journal:  JAMA       Date:  1999-01-13       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.